Company Analysis CONMED Corporation
1. Summary
Advantages
- Current debt level 42.67% is below 100% and has decreased over 5 years from 43.31%.
- The company's current efficiency (ROE=7.73%) is higher than the sector average (ROE=-80.86%)
Disadvantages
- Price (68.82 $) is higher than fair price (27.38 $)
- Dividends (1.21%) are below the sector average (1.31%).
- The stock's return over the last year (-26.67%) is lower than the sector average (-0.7555%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| CONMED Corporation | Healthcare | Index | |
|---|---|---|---|
| 7 days | 1.6% | 2.4% | -0.4% |
| 90 days | 10.7% | -4.9% | 1.5% |
| 1 year | -26.7% | -0.8% | 21.8% |
CNMD vs Sector: CONMED Corporation has significantly underperformed the "Healthcare" sector by -25.91% over the past year.
CNMD vs Market: CONMED Corporation has significantly underperformed the market by -48.45% over the past year.
Stable price: CNMD is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CNMD with weekly volatility of -0.5129% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (68.82 $) is higher than the fair price (27.38 $).
Price is higher than fair: The current price (68.82 $) is 60.2% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (55.25) is lower than that of the sector as a whole (57.87).
P/E vs Market: The company's P/E (55.25) is higher than that of the market as a whole (47.68).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.27) is lower than that of the sector as a whole (9.39).
P/BV vs Market: The company's P/BV (4.27) is lower than that of the market as a whole (22.59).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (2.87) is lower than that of the sector as a whole (4.07).
P/S vs Market: The company's P/S indicator (2.87) is lower than that of the market as a whole (15.21).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (24.85) is higher than that of the sector as a whole (17.62).
EV/Ebitda vs Market: The company's EV/Ebitda (24.85) is higher than that of the market as a whole (24.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 108.92% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (108.92%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-66.62%).
5.4. ROE
ROE vs Sector: The company's ROE (7.73%) is higher than that of the sector as a whole (-80.86%).
ROE vs Market: The company's ROE (7.73%) is lower than that of the market as a whole (18.08%).
5.5. ROA
ROA vs Sector: The company's ROA (2.8%) is lower than that of the sector as a whole (6.71%).
ROA vs Market: The company's ROA (2.8%) is lower than that of the market as a whole (6.49%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (6.24%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (6.24%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 1.21% is below the average for the sector '1.31%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 1.21% has been steadily paid over the past 7 years, DSI=1.
Weak dividend growth: The company's dividend yield 1.21% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (38.01%) are at a comfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 31.05.2024 | Schwarzentraub Barbara J Director |
Purchase | 77.79 | 23 493 | 302 |
| 31.05.2024 | Council LaVerne H Director |
Purchase | 77.79 | 23 493 | 302 |
| 31.05.2024 | Aronson Martha Goldberg Director |
Purchase | 77.79 | 23 493 | 302 |
| 31.05.2024 | Farkas Charles Director |
Purchase | 77.79 | 23 493 | 302 |
| 31.05.2024 | BRONSON DAVID M Director |
Purchase | 77.79 | 23 493 | 302 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
